Praxis Precision Medicines Inc Forecast, price target & analysts
Praxis Precision Medicines Inc Target price 2025 - Analyst rating & recommendation
Praxis Precision Medicines Inc Classifications & Recommendation:
Praxis Precision Medicines Inc Price Target
| Target Price | $160.46 |
| Price | $65.03 |
| Potential |
146.74%
register free of charge
|
| Number of Estimates | 11 |
|
11 Analysts have issued a price target Praxis Precision Medicines Inc 2026 .
The average Praxis Precision Medicines Inc target price is $160.46.
This is
146.74%
register free of charge
$305.00
369.01%
register free of charge
$57.00
12.35%
register free of charge
|
|
| A rating was issued by 11 analysts: 10 Analysts recommend Praxis Precision Medicines Inc to buy, 1 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Praxis Precision Medicines Inc stock has an average upside potential 2026 of
146.74%
register free of charge
|
Sales and Margin forecast 2024, 2025 to 2028
| Dec '23 |
2024 Estimates |
|
|---|---|---|
| Revenue Million $ | 2.45 | 1.46 |
| 40.28% | ||
| EBITDA Margin | -5,140.41% | -13,276.74% |
| 158.28% | ||
| Net Margin | -13,571.23% | -12,364.78% |
| 8.89% |
11 Analysts have issued a sales forecast Praxis Precision Medicines Inc 2024 . The average Praxis Precision Medicines Inc sales estimate is
This results in the following potential growth metrics:
2 Analysts have issued an Praxis Precision Medicines Inc EBITDA forecast 2024. The average Praxis Precision Medicines Inc EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
5 Praxis Precision Medicines Inc Analysts have issued a net profit forecast 2024. The average Praxis Precision Medicines Inc net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2024, 2025 to 2028
| Dec '23 |
2024 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -18.69 | -10.17 |
| 73.17% | 45.59% | |
| P/E | negative | |
| EV/Sales | 585.48 |
5 Analysts have issued a Praxis Precision Medicines Inc forecast for earnings per share. The average Praxis Precision Medicines Inc <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is
This results in the following potential growth metrics and future valuations:
Based on analysts' sales estimates for 2024, the Praxis Precision Medicines Inc stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of
This results in the following potential growth metrics and future valuations:
Praxis Precision Medicines Inc...
Current Praxis Precision Medicines Inc Upgrades & Downgrades Beta
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Deutsche Bank | Locked ➜ Locked | Locked | Feb 11 2025 |
| Needham | Locked ➜ Locked | Locked | Feb 10 2025 |
| Truist Securities | Locked ➜ Locked | Locked | Jan 21 2025 |
| HC Wainwright & Co. | Locked ➜ Locked | Locked | Dec 12 2024 |
| HC Wainwright & Co. | Locked ➜ Locked | Locked | Nov 07 2024 |
| Needham | Locked ➜ Locked | Locked | Nov 07 2024 |
| Oppenheimer | Locked ➜ Locked | Locked | Oct 31 2024 |
| Analyst Rating | Date |
|---|---|
|
Locked
Deutsche Bank: Locked ➜ Locked
|
Feb 11 2025 |
|
Locked
Needham: Locked ➜ Locked
|
Feb 10 2025 |
|
Locked
Truist Securities: Locked ➜ Locked
|
Jan 21 2025 |
|
Locked
HC Wainwright & Co.: Locked ➜ Locked
|
Dec 12 2024 |
|
Locked
HC Wainwright & Co.: Locked ➜ Locked
|
Nov 07 2024 |
|
Locked
Needham: Locked ➜ Locked
|
Nov 07 2024 |
|
Locked
Oppenheimer: Locked ➜ Locked
|
Oct 31 2024 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
